Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

827 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Durgeau A, et al. Among authors: eggermont a. Nat Commun. 2018 Nov 30;9(1):5097. doi: 10.1038/s41467-018-07603-1. Nat Commun. 2018. PMID: 30504837 Free PMC article.
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Besse B, et al. Among authors: eggermont a. Oncoimmunology. 2015 Aug 12;5(4):e1071008. doi: 10.1080/2162402X.2015.1071008. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141373 Free PMC article.
Tumor plasticity interferes with anti-tumor immunity.
Chouaib S, Janji B, Tittarelli A, Eggermont A, Thiery JP. Chouaib S, et al. Among authors: eggermont a. Crit Rev Immunol. 2014;34(2):91-102. doi: 10.1615/critrevimmunol.2014010183. Crit Rev Immunol. 2014. PMID: 24940910 Review.
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C. Cerezo M, et al. Among authors: eggermont am. Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29. Nat Med. 2018. PMID: 30374200
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: eggermont a. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: eggermont am. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
Potent immunomodulatory effects of the trifunctional antibody catumaxomab.
Goéré D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L. Goéré D, et al. Among authors: eggermont a. Cancer Res. 2013 Aug 1;73(15):4663-73. doi: 10.1158/0008-5472.CAN-12-4460. Epub 2013 Jun 4. Cancer Res. 2013. PMID: 23737485
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Among authors: eggermont a. Oncoimmunology. 2013 May 1;2(5):e24238. doi: 10.4161/onci.24238. Oncoimmunology. 2013. PMID: 23762803 Free PMC article.
827 results